Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells

• DOI: 10.1007/s00432-023-05471-x
• Publication Date: 2023-10-31T07:02:31Z
• Authors: Baoling Xing; Xiaoying Zhang; Xia Gu; Lintao Xiang; Cuiping Wang; Yueling Jin
• Keywords: DNA-Binding Proteins; Phosphatidylinositol 3-Kinases; Mutation; Humans; Nuclear Proteins; Female; Proto-Oncogene Proteins c-akt; 3. Good health; Transcription Factors; Endometrial Neoplasms

Abstract Purpose As one of the most common gynecologic malignancies, endometrial cancer (EC) is driven by multiple genetic alterations that may be targeted for treatments. AT-rich interaction domain 1A (ARID1A) gene mutations were reported as early events in endometrial carcinogenesis. Methods To explore the alterations of downstream molecular pathways caused by ARID1A mutations and the associated therapeutic implications, we edited ARID1A gene in human endometrial cancer cell line Ishikawa using the Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-Associated Proteins (CRISPR/Cas9) technology. We successfully constructed a stable Ishikawa cell line with a confirmed 10bp deletion on the ARID1A gene, which resulted in a code-shift mutation and gene knockout. Results Compared with unedited wild-type cells, ARID1A knockout (KO) led to reduced apoptosis, accelerated transformation from G0/G1 to S phase and enhanced cell proliferation. In addition, ARID1A KO resulted in high levels of microsatellite instability (MSI-H). Moreover, transcriptomic analyses showed that ARID1A KO can lead to activated phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling. Furthermore, experimental analyses demonstrated that ARID1A KO cells had reduced expression of genetic instability-associated markers mutL homologue 1 (MLH1) and progesterone receptor B (PR), and increased p-Akt expression. Conclusion These findings support further exploration of ARID1A as a therapeutic target for EC, and provide insights in developing more effective treatments in EC, such as the combinatory use of immune checkpoint inhibitors.